Insider Buying: PetVivo Holdings, Inc. (NASDAQ:PETV) CEO Buys 150,000 Shares of Stock

PetVivo Holdings, Inc. (NASDAQ:PETV) CEO John Lai purchased 150,000 shares of PetVivo stock in a transaction on Monday, April 15th. The shares were acquired at an average cost of $0.60 per share, for a total transaction of $90,000.00. Following the purchase, the chief executive officer now owns 1,288,592 shares in the company, valued at $773,155.20. The acquisition was disclosed in a document filed with the SEC, which is available through this link.

PetVivo Stock Performance

Shares of PetVivo stock opened at $0.72 on Friday. PetVivo Holdings, Inc. has a fifty-two week low of $0.33 and a fifty-two week high of $2.90. The business’s fifty day moving average is $1.02 and its two-hundred day moving average is $1.16. The company has a debt-to-equity ratio of 0.02, a current ratio of 0.90 and a quick ratio of 0.62.

PetVivo (NASDAQ:PETV) last issued its quarterly earnings results on Monday, February 12th. The company reported ($0.12) earnings per share for the quarter. The business had revenue of $0.60 million for the quarter. PetVivo had a negative return on equity of 1,319.59% and a negative net margin of 1,016.64%.

Institutional Trading of PetVivo

Institutional investors and hedge funds have recently made changes to their positions in the company. Warberg Asset Management LLC acquired a new stake in shares of PetVivo during the 4th quarter worth $29,000. HighTower Advisors LLC acquired a new stake in shares of PetVivo during the 1st quarter worth $40,000. Finally, Vanguard Group Inc. increased its holdings in shares of PetVivo by 5.2% during the 1st quarter. Vanguard Group Inc. now owns 226,137 shares of the company’s stock worth $461,000 after buying an additional 11,251 shares during the last quarter. 24.55% of the stock is currently owned by institutional investors and hedge funds.

About PetVivo

PetVivo Holdings, Inc, a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses.